Business profile & competitive position
The Cooper Companies, Inc. operates in the Healthcare sector under the Medical - Instruments & Supplies industry. The business is split into two distinct segments. CooperVision develops, manufactures and markets a broad range of contact lenses, including single-use, two-week and monthly lenses plus specialty eyecare products such as silicone hydrogel lenses, orthokeratology lenses and scleral lenses. CooperSurgical supplies more than 600 products and services focused on fertility and women’s health, including medical devices for gynecology, obstetrics, contraception and labor and delivery, along with cord blood and tissue storage, IVF support, donor gametes, cryopreservation and genomic services.
The company’s products are sold in over 130 countries and reach more than fifty million lives annually. Its MiSight 1 day lens is approved by the FDA, Chinese NMPA and Japanese MHLW to slow the progression of, and correct, myopia in age-appropriate children. On the profitability side, Cooper Companies currently posts a net margin of 13.5% and a return on equity of 6.9%, with a beta of 0.82. The 13.5% net margin is solid relative to broader healthcare but not especially wide for a premium medical-device franchise, while the 6.9% ROE suggests the business is not generating outsized returns on shareholder capital at this snapshot. Those figures paint a picture of a stable, globally diversified med-tech operator rather than a high-return compounder. The company also maintains approximately 500 research-and-development employees across both segments.
Financial posture
Cooper Companies currently carries an $11.7 billion market capitalization and trades at a P/E ratio of 20.9, based on the current snapshot price of $61.295. The 13.5% net margin and 6.9% ROE frame the valuation: the stock is priced at a modest discount to many high-growth medical-device peers, reflecting the lower capital-efficiency profile. The beta of 0.82 implies the stock has historically moved less dramatically than the broader market, though recent headlines show it is not immune to sharp single-day moves.
From a technical reference point, the stock closed at $61.295 with an RSI of 59.0 and a 50-day EMA of $60.60. That places the current price just above its 50-day moving average and near the middle of the RSI range, neither oversold nor overbought by conventional readings. The combination of a sub-market beta, a 20.9x P/E and mid-single-digit ROE points to a valuation that assumes steady, but not explosive, earnings growth rather than a high-multiple growth premium.
Strategic priorities & outlook
The company’s most recent SEC 10-K filing outlines a clear set of operational priorities. CooperVision is focused on expanding worldwide market penetration for recently introduced products and building its presence in both existing and emerging markets. To support that growth, it is increasing investment in distribution and packaging capabilities. Separately, CooperVision is also investing to develop the myopia management market by educating eye care practitioners, patients and families, which aligns with the regulatory-backed positioning of MiSight 1 day.
On the CooperSurgical side, the stated strategy is to continue investing in the business, including through strategic transactions, to expand its integrated solutions model within fertility and women’s health. The filing also notes that the company’s products are sold in over 130 countries and that it employs roughly 500 people in R&D across both segments. Taken together, the priorities suggest near-term capital will flow toward geographic expansion, supply-chain capacity and M&A-driven portfolio depth rather than a single blockbuster product bet.
Macro & geopolitical exposure
As a Medical - Instruments & Supplies company with global distribution, Cooper Companies is exposed to several macro themes that flow directly from its industry classification. Regulatory risk is at the top of the list. Contact lenses and fertility devices face approval and compliance requirements from agencies such as the FDA, China’s NMPA and Japan’s MHLW. Any change in regulatory timelines, labeling requirements or reimbursement status can affect commercial timelines in major markets.
Because products are sold in over 130 countries, currency exposure is material. A stronger U.S. dollar can compress translated overseas revenue, while local-currency weakness in emerging markets can pressure pricing power. Trade policy is another relevant factor: tariffs or supply-chain restrictions on raw materials, packaging components and finished medical devices can raise costs or disrupt distribution. The company’s discussion of increasing investment in distribution and packaging also implies sensitivity to logistics and input costs. Finally, demographic trends influence demand: myopia prevalence supports CooperVision’s long-term market, while fertility trends and healthcare policy around women’s health shape CooperSurgical’s addressable opportunity.
Recent developments
The most recent news flow has been dominated by securities-investigation headlines following a sharp share-price decline. On October 30, 2026, PR Newswire reported that The Cooper Companies was being scrutinized over U.S. channel inventory reductions that drove the stock sharply lower. That same day, Newsfile reported that Rosen, a plaintiff-side investor counsel, was encouraging Cooper Companies investors to inquire about a securities class-action investigation. Also on October 30, 2026, Globenewswire reported that Glancy Prongay & Wolke Rotter LLP was continuing an investigation into possible securities fraud after a 14.67% share-price drop. A day earlier, on October 29, 2026, Globenewswire carried another Rosen Law Firm notice encouraging investors who suffered losses to contact the firm about their rights.
The 14.67% drop referenced in those releases matches the next-day move from the September 9, 2026 earnings reaction. The cluster of headlines underscores that the market is currently focused on whether management’s communications around inventory and channel dynamics were adequate, a separate issue from whether the underlying earnings per share figure beat or missed.
Earnings behavior & post-earnings drift
Cooper Companies has delivered a perfect beat rate over the last eight reported quarters, beating estimates in all eight instances, with an average earnings surprise of 4.2%. Yet the average 5-day price move after those reports was negative 2.34%, and the post-earnings drift direction is classified as “down.” That is a meaningful disconnect for readers who assume a beat reliably produces a sustained rally.
The last four quarters illustrate the pattern clearly. On December 4, 2025, the company reported actual EPS of $1.15 against an estimate of $1.11, a 3.6% surprise, and the stock rose 5.67% the next day and 6.59% over the following five days. On March 5, 2026, actual EPS of $1.10 beat the $1.03 estimate by 6.8%, but the stock fell 4.55% the next day and 10.82% over the next five days. On June 4, 2026, actual EPS of $1.21 beat the $1.10 estimate by 10%, and the stock rallied 8.58% the next day and 8.85% over five days. Most recently, on September 9, 2026, actual EPS of $1.15 beat the $1.12 estimate by 2.7%, yet the stock plunged 14.67% the next day and 13.97% over the following five days.
The pattern shows that even on beat quarters, the reaction depends heavily on what the market’s real expectation was beyond the published consensus and on management’s forward commentary. The September report is the clearest example: the reported number beat, but the trajectory of the business and the channel-inventory narrative overwhelmed the EPS beat. The next report is scheduled for December 3, 2026 after the close, with a consensus EPS estimate of $1.07.
For a deeper dive into how institutional analysts are interpreting these cross-currents, readers should consult the full institutional verdict, which aggregates current ratings, estimate revisions and price-target context for the stock.
Frequently Asked Questions
What does The Cooper Companies actually sell?
The company operates two segments: CooperVision, which sells contact lenses and specialty eyecare products, and CooperSurgical, which offers more than 600 products and services for fertility and women’s health.
Why did the stock drop 14.67% after a recent earnings beat?
On September 9, 2026, Cooper Companies reported EPS of $1.15 versus an estimate of $1.12, but the stock fell 14.67% the next day. News reports tied the decline to concerns around U.S. channel inventory reductions and weaker forward business momentum rather than the headline EPS result.
What is Cooper Companies’ earnings beat rate and post-earnings drift?
Over the last eight reported quarters, Cooper Companies has beaten earnings estimates 100% of the time with an average surprise of 4.2%. Despite that, the average 5-day post-earnings drift was negative 2.34%, showing that beats have not consistently produced sustained upward moves.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-09-09 | $1.15 | $1.12 | +2.7% | -14.67% | -13.97% |
| 2026-06-04 | $1.21 | $1.1 | +10% | +8.58% | +8.85% |
| 2026-03-05 | $1.1 | $1.03 | +6.8% | -4.55% | -10.82% |
| 2025-12-04 | $1.15 | $1.11 | +3.6% | +5.67% | +6.59% |
| 2025-08-27 | $1.1 | $1.07 | +2.8% | - | - |
| 2025-05-29 | $0.96 | $0.928 | +3.4% | - | - |
Previous COO editions
Get the institutional verdict on COO
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the COO verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.